Could this be the secret to Pfizer's rebound strategy?
It could prove to be a case of better later than never for the healthcare giant.
Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and entertainment news.
Albert Bourla, Pfizer Chairman & CEO, addresses the current state of US vaccinations and the robust growth in Pfizer's ...
Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...
By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...
The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...
Pfizer said on Thursday that finance chief Dave Denton will leave on August 15 to return to the consumer goods industry.
Shares of Pfizer Inc. PFE slipped 1.19% to $24.08 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.79% to 7,499.36 and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results